MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Pfizer

Geschlossen

BrancheGesundheitswesen

25.68 -2.21

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

25.63

Max

26.47

Schlüsselkennzahlen

By Trading Economics

Einkommen

-45M

2.9B

Verkäufe

938M

15B

KGV

Branchendurchschnitt

13.984

37.257

EPS

0.78

Dividendenrendite

6.21

Gewinnspanne

19.982

Angestellte

81,000

EBITDA

266M

5.3B

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

+8.6% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

6.21%

2.94%

Nächstes Ergebnis

4. Nov. 2025

Nächste Dividendenausschüttung

1. Dez. 2025

Nächstes Ex-Dividendendatum

7. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

16B

150B

Vorheriger Eröffnungskurs

27.89

Vorheriger Schlusskurs

25.68

Nachrichtenstimmung

By Acuity

40%

60%

163 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

Pfizer Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

1. Okt. 2025, 08:54 UTC

Wichtige Markttreiber

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

30. Sept. 2025, 15:07 UTC

Wichtige Markttreiber

Pfizer Shares Rise After WSJ Reports Company Will Lower Drug Costs

22. Sept. 2025, 14:54 UTC

Akquisitionen, Fusionen, Übernahmen

Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion -- 2nd Update

22. Sept. 2025, 11:51 UTC

Akquisitionen, Fusionen, Übernahmen

Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion -- Update

22. Sept. 2025, 11:09 UTC

Akquisitionen, Fusionen, Übernahmen

Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion

22. Sept. 2025, 10:13 UTC

Wichtige Markttreiber
Akquisitionen, Fusionen, Übernahmen

Metsera Shares Leap Premarket on Report of Takeover by Pfizer

22. Sept. 2025, 07:42 UTC

Akquisitionen, Fusionen, Übernahmen

Pfizer Nears $7.3 Billion Metsera Deal, FT Says, Citing Sources

5. Aug. 2025, 11:34 UTC

Ergebnisse

Pfizer Boosts 2025 Adjusted EPS Outlook Following 2Q Gains

22. Sept. 2025, 15:17 UTC

Akquisitionen, Fusionen, Übernahmen

Pfizer Jumps Back into the Weight-Loss Race With $4.9B Acquisition -- Barrons.com

22. Sept. 2025, 13:43 UTC

Akquisitionen, Fusionen, Übernahmen

Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion -- Update

22. Sept. 2025, 11:26 UTC

Akquisitionen, Fusionen, Übernahmen

These Stocks Are Moving the Most Today: Fox, Coinbase, Metsera, Pfizer, Kenvue, Anywhere Real Estate, Premier, and More -- Barrons.com

22. Sept. 2025, 11:26 UTC

Akquisitionen, Fusionen, Übernahmen

Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion -- WSJ

22. Sept. 2025, 10:48 UTC

Akquisitionen, Fusionen, Übernahmen

Pfizer: Metsera Deal Adds Four Clinical-Stage Incretin, Amylin Programs to Pipeline >PFE MTSR

22. Sept. 2025, 10:47 UTC

Akquisitionen, Fusionen, Übernahmen

Pfizer: Metsera Deal Includes Contingent Value Rights Worth Up to Additional $22.50/Share >PFE MTSR

22. Sept. 2025, 10:46 UTC

Akquisitionen, Fusionen, Übernahmen

Pfizer: Metsera Deal Has Initial Enterprise Value of $4.9 Billion >PFE MTSR

22. Sept. 2025, 10:45 UTC

Akquisitionen, Fusionen, Übernahmen

Pfizer to Pay Initial $47.50/Share for Metsera >PFE MTSR

22. Sept. 2025, 10:45 UTC

Akquisitionen, Fusionen, Übernahmen

Pfizer to Acquire Metsera and Its Next-Generation Obesity Portfolio >PFE MTSR

22. Sept. 2025, 09:12 UTC

Heiße Aktien

Stocks to Watch Monday: Nippon Steel, Porsche, Infosys, Metsera -- WSJ

5. Aug. 2025, 20:44 UTC

Ergebnisse

These Stocks Moved the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5. Aug. 2025, 18:20 UTC

Ergebnisse

Pfizer Stock Rises as Earnings Smash Expectations. But These Challenges Remain. -- Barrons.com

5. Aug. 2025, 18:17 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5. Aug. 2025, 16:04 UTC

Market Talk

Pfizer's New Tax Rate Helps Boost Adj EPS Outlook -- Market Talk

5. Aug. 2025, 15:25 UTC

Ergebnisse

Correction to These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Caterpillar, BP, and More -- Barrons.com

5. Aug. 2025, 13:56 UTC

Ergebnisse

Pfizer Stock Rises as Earnings Smash Expectations. But These Challenges Remain. -- Barrons.com

5. Aug. 2025, 11:43 UTC

Ergebnisse

Pfizer Stock Pops as Earnings Smash Expectations. Guidance Hiked in Face of Tariffs. -- Barrons.com

5. Aug. 2025, 11:27 UTC

Ergebnisse

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5. Aug. 2025, 10:57 UTC

Ergebnisse

Pfizer Stock Pops as Earnings Smash Expectations. Why the Outlook Has Been Hiked. -- Barrons.com

5. Aug. 2025, 10:55 UTC

Ergebnisse

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5. Aug. 2025, 10:53 UTC

Ergebnisse

Pfizer Boosts 2025 Profit Estimate In A Sign Of 'Confidence' -- MarketWatch

5. Aug. 2025, 10:51 UTC

Ergebnisse

Pfizer: On Track to Deliver About $7.2B Overall Cost Savings From Cost-Improvement Initiatives b/ End of 2027 >PFE

Peer-Vergleich

Kursveränderung

Pfizer Prognose

Kursziel

By TipRanks

8.6% Vorteil

12-Monats-Prognose

Durchschnitt 28.53 USD  8.6%

Hoch 34 USD

Tief 24 USD

Basierend auf 17 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Pfizer – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

17 ratings

4

Buy

12

Halten

1

Sell

Technischer Score

By Trading Central

22.855 / 23.85Unterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

163 / 371 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
help-icon Live chat